PL2238255T3 - Wektory arenawirusowe z defektem replikacji - Google Patents
Wektory arenawirusowe z defektem replikacjiInfo
- Publication number
- PL2238255T3 PL2238255T3 PL08868316T PL08868316T PL2238255T3 PL 2238255 T3 PL2238255 T3 PL 2238255T3 PL 08868316 T PL08868316 T PL 08868316T PL 08868316 T PL08868316 T PL 08868316T PL 2238255 T3 PL2238255 T3 PL 2238255T3
- Authority
- PL
- Poland
- Prior art keywords
- replication
- arenavirus vectors
- defective arenavirus
- defective
- vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
- C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07025099 | 2007-12-27 | ||
EP08868316.4A EP2238255B1 (en) | 2007-12-27 | 2008-12-22 | Replication-defective arenavirus vectors |
PCT/EP2008/010994 WO2009083210A1 (en) | 2007-12-27 | 2008-12-22 | Replication-defective arenavirus vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2238255T3 true PL2238255T3 (pl) | 2014-02-28 |
Family
ID=40428182
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13152727.7T PL2604695T3 (pl) | 2007-12-27 | 2008-12-22 | Cząstka arenawirusa z defektem replikacji |
PL08868316T PL2238255T3 (pl) | 2007-12-27 | 2008-12-22 | Wektory arenawirusowe z defektem replikacji |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13152727.7T PL2604695T3 (pl) | 2007-12-27 | 2008-12-22 | Cząstka arenawirusa z defektem replikacji |
Country Status (16)
Country | Link |
---|---|
US (6) | US8592205B2 (pl) |
EP (3) | EP4186978A1 (pl) |
JP (3) | JP5642556B2 (pl) |
CN (3) | CN101918565B (pl) |
CA (1) | CA2744910C (pl) |
DK (2) | DK2238255T3 (pl) |
ES (2) | ES2438773T3 (pl) |
FI (1) | FI2604695T3 (pl) |
HK (1) | HK1151829A1 (pl) |
HR (1) | HRP20221475T3 (pl) |
HU (1) | HUE061060T2 (pl) |
LT (1) | LT2604695T (pl) |
PL (2) | PL2604695T3 (pl) |
PT (1) | PT2604695T (pl) |
SI (1) | SI2604695T1 (pl) |
WO (1) | WO2009083210A1 (pl) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4186978A1 (en) | 2007-12-27 | 2023-05-31 | Universität Zürich | Replication-defective arenavirus vectors |
US20120219576A1 (en) * | 2009-09-16 | 2012-08-30 | The Administrators Of The Tulane Educational Fund | Lassa virus-like particles and methods of production thereof |
US20130209406A1 (en) * | 2010-06-06 | 2013-08-15 | Benjamin R. tenOever | Recombinant rna viruses and uses thereof |
WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
EP3662935A1 (en) * | 2011-07-11 | 2020-06-10 | Inovio Pharmaceuticals, Inc. | Cross-protective arenavirus vaccines and their method of use |
DK2970398T3 (da) | 2013-03-13 | 2024-08-05 | Us Health | Præfusions-rsv-f-proteiner og anvendelse deraf |
WO2014140301A1 (en) | 2013-03-15 | 2014-09-18 | Université De Genève | Anti-mycobacterial vaccines |
AU2014359276B2 (en) * | 2013-12-03 | 2021-01-28 | Hookipa Biotech Gmbh | CMV vaccines |
WO2015123592A2 (en) | 2014-02-13 | 2015-08-20 | Synthetic Genomics, Inc. | Recombinant rna particles and methods of use |
EP3505623A1 (en) | 2014-02-14 | 2019-07-03 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
MX2017003694A (es) * | 2014-09-22 | 2017-10-12 | Univ Minnesota | Sistema de genética inversa del virus pichindé y métodos de uso. |
SI3218504T1 (sl) * | 2014-11-13 | 2020-11-30 | Universite De Geneve | Tri-segmentirani arenavirusi kot vakcinski vektorji |
DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
CN107921117B (zh) * | 2015-06-10 | 2022-06-07 | 霍欧奇帕生物科技有限公司 | Hpv疫苗 |
WO2018045029A1 (en) * | 2016-09-02 | 2018-03-08 | The United States Of America, As Represented By The Secretary Of The Army | Pan south american arenavirus live attenuated vaccine |
DK3371316T3 (da) * | 2015-11-04 | 2023-01-23 | Hookipa Biotech Gmbh | Vacciner mod hepatitis b-virus |
LT3373959T (lt) | 2015-11-12 | 2022-07-25 | Hookipa Biotech Gmbh | Arenavirusų dalelės, kaip vėžio vakcinos |
US11260090B2 (en) * | 2016-03-08 | 2022-03-01 | University Of Vermont And State Agricultural College | Modified arenavirus |
IL262963B1 (en) * | 2016-05-18 | 2024-09-01 | Hookipa Biotech Gmbh | Three-segmented PICHINDE viruses as vaccine vectors |
US20200206334A1 (en) | 2016-11-04 | 2020-07-02 | Hookipa Biotech Gmbh | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
WO2018109220A2 (en) | 2016-12-16 | 2018-06-21 | Institute For Research In Biomedicine | Novel recombinant prefusion rsv f proteins and uses thereof |
WO2018185307A1 (en) | 2017-04-07 | 2018-10-11 | Hookipa Biotech Ag | Arenavirus particles to treat solid tumors |
DE102018215551A1 (de) | 2018-09-12 | 2020-03-12 | Virolutions Biotech Gmbh | Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten |
WO2020255023A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof |
AU2020315598A1 (en) | 2019-07-16 | 2022-03-03 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
BR112022005687A2 (pt) | 2019-09-30 | 2022-06-21 | Gilead Sciences Inc | Vacinas contra o hbv e métodos para tratar o hbv |
US20220362361A1 (en) * | 2019-10-18 | 2022-11-17 | University Of Virginia Patent Foundation | Compositions and methods for producing enhanced immune responses and rapid antibody production |
JP2023500928A (ja) | 2019-11-07 | 2023-01-11 | ユニベルシタト バーゼル | ベクターとしてのアレナウイルス |
CA3202466A1 (en) | 2021-01-14 | 2022-07-21 | Jiani LI | Hiv vaccines and methods of using |
IL305965A (en) | 2021-03-23 | 2023-11-01 | Hookipa Biotech Gmbh | ARENAVIRUSES USED IN PROSTATE CANCER TREATMENTS |
US20240229073A1 (en) | 2021-05-13 | 2024-07-11 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
IL312429A (en) | 2021-11-08 | 2024-06-01 | Hookipa Biotech Gmbh | Tailored RNAV Particles Expressing Mutant KRAS, a Mutated Cancer Executive Gene, or Tumor-Associated Antigen as Cancer Immunotherapy |
WO2023152116A1 (en) | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
CN117343911A (zh) * | 2022-06-28 | 2024-01-05 | 中国科学院上海药物研究所 | 一种缺陷型丝状病毒的制备方法及其应用 |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
CN117264909A (zh) * | 2023-10-25 | 2023-12-22 | 深圳湾实验室 | 反式互补缺陷猴痘病毒及其应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
US7267823B2 (en) | 1998-06-29 | 2007-09-11 | United States Of America As Represented By The Secretary Of The Army | Ebola peptides and immunogenic compositions containing same |
DE19856463B4 (de) * | 1998-11-26 | 2006-02-02 | Heinrich-Pette-Institut | Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren |
JP2000279178A (ja) * | 1999-02-24 | 2000-10-10 | Japan Found Cancer Res | ウイルスベクター |
WO2003090002A1 (en) | 2002-04-17 | 2003-10-30 | Astropower, Inc. | Maximum power sensor for photovoltaic system |
US7135339B2 (en) * | 2003-11-20 | 2006-11-14 | University Of Iowa Research Foundation | Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) |
WO2005061534A2 (en) | 2003-12-23 | 2005-07-07 | Statens Serum Institut | Improved tuberculosis vaccines |
KR101255870B1 (ko) | 2004-11-16 | 2013-04-17 | 아에라스 글로벌 티비 백신 파운데이션 | 재조합 바이러스 벡터를 포함하는 다가 백신 |
DE102005006388A1 (de) | 2005-02-11 | 2006-08-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Replikationsdefiziente RNA-Viren als Impfstoffe |
US20070005929A1 (en) * | 2005-06-30 | 2007-01-04 | Post Daniel J | Method, system, and article of manufacture for sector mapping in a flash device |
EP4186978A1 (en) | 2007-12-27 | 2023-05-31 | Universität Zürich | Replication-defective arenavirus vectors |
WO2012093340A2 (en) | 2011-01-07 | 2012-07-12 | Bioscience Slovakia | Viral diagnostics |
WO2014140301A1 (en) | 2013-03-15 | 2014-09-18 | Université De Genève | Anti-mycobacterial vaccines |
AU2014359276B2 (en) | 2013-12-03 | 2021-01-28 | Hookipa Biotech Gmbh | CMV vaccines |
SI3218504T1 (sl) | 2014-11-13 | 2020-11-30 | Universite De Geneve | Tri-segmentirani arenavirusi kot vakcinski vektorji |
CN107921117B (zh) | 2015-06-10 | 2022-06-07 | 霍欧奇帕生物科技有限公司 | Hpv疫苗 |
DK3371316T3 (da) | 2015-11-04 | 2023-01-23 | Hookipa Biotech Gmbh | Vacciner mod hepatitis b-virus |
LT3373959T (lt) | 2015-11-12 | 2022-07-25 | Hookipa Biotech Gmbh | Arenavirusų dalelės, kaip vėžio vakcinos |
IL262963B1 (en) | 2016-05-18 | 2024-09-01 | Hookipa Biotech Gmbh | Three-segmented PICHINDE viruses as vaccine vectors |
US20200206334A1 (en) | 2016-11-04 | 2020-07-02 | Hookipa Biotech Gmbh | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
WO2018185307A1 (en) | 2017-04-07 | 2018-10-11 | Hookipa Biotech Ag | Arenavirus particles to treat solid tumors |
JP2023500928A (ja) | 2019-11-07 | 2023-01-11 | ユニベルシタト バーゼル | ベクターとしてのアレナウイルス |
CR20220602A (es) | 2020-05-29 | 2023-05-16 | Hookipa Biotech Gmbh | Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus |
-
2008
- 2008-12-22 EP EP22207314.0A patent/EP4186978A1/en active Pending
- 2008-12-22 CA CA2744910A patent/CA2744910C/en active Active
- 2008-12-22 CN CN200880123157.6A patent/CN101918565B/zh active Active
- 2008-12-22 LT LTEP13152727.7T patent/LT2604695T/lt unknown
- 2008-12-22 PL PL13152727.7T patent/PL2604695T3/pl unknown
- 2008-12-22 DK DK08868316.4T patent/DK2238255T3/da active
- 2008-12-22 JP JP2010540060A patent/JP5642556B2/ja active Active
- 2008-12-22 ES ES08868316.4T patent/ES2438773T3/es active Active
- 2008-12-22 ES ES13152727T patent/ES2937147T3/es active Active
- 2008-12-22 CN CN2012104612347A patent/CN103255169A/zh active Pending
- 2008-12-22 HR HRP20221475TT patent/HRP20221475T3/hr unknown
- 2008-12-22 SI SI200832203T patent/SI2604695T1/sl unknown
- 2008-12-22 CN CN201410126161.5A patent/CN103993012B/zh active Active
- 2008-12-22 US US12/810,382 patent/US8592205B2/en active Active
- 2008-12-22 PT PT131527277T patent/PT2604695T/pt unknown
- 2008-12-22 WO PCT/EP2008/010994 patent/WO2009083210A1/en active Application Filing
- 2008-12-22 EP EP08868316.4A patent/EP2238255B1/en active Active
- 2008-12-22 EP EP13152727.7A patent/EP2604695B1/en active Active
- 2008-12-22 HU HUE13152727A patent/HUE061060T2/hu unknown
- 2008-12-22 FI FIEP13152727.7T patent/FI2604695T3/fi active
- 2008-12-22 PL PL08868316T patent/PL2238255T3/pl unknown
- 2008-12-22 DK DK13152727.7T patent/DK2604695T3/da active
-
2011
- 2011-06-10 HK HK11105913.0A patent/HK1151829A1/xx unknown
-
2013
- 2013-10-23 US US14/061,025 patent/US9309289B2/en active Active
-
2014
- 2014-07-25 JP JP2014151617A patent/JP2014239688A/ja active Pending
-
2016
- 2016-03-14 US US15/069,773 patent/US9944952B2/en active Active
- 2016-11-07 JP JP2016216877A patent/JP6227094B2/ja active Active
-
2018
- 2018-03-21 US US15/928,003 patent/US10655145B2/en active Active
-
2020
- 2020-04-29 US US16/861,758 patent/US11401528B2/en active Active
-
2022
- 2022-06-22 US US17/846,817 patent/US20220315951A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1151829A1 (en) | Replication-defective arenavirus vectors | |
GB2455302B (en) | Improved skateboard | |
GB0706914D0 (en) | Novel adenovirus vectors | |
PL2121660T3 (pl) | Amidy grzybobójcze | |
KR101608166B9 (ko) | 펌프 카세트 | |
AU318043S (en) | Impeller | |
GB0718224D0 (en) | E;ectricalsupply revies | |
EP2155343A4 (en) | SNOWBOARD | |
AU318968S (en) | Dock insert | |
GB0810912D0 (en) | Vector | |
GB0820631D0 (en) | Vectors | |
GB0914445D0 (en) | Flexible secure enclosure | |
ZA201002750B (en) | Inflatable chamber-pot | |
GB0713179D0 (en) | Vectors for cloning | |
GB0723387D0 (en) | Improved dehumldifier | |
GB0702694D0 (en) | Vectors | |
GB2452328B (en) | Improved skate | |
GB0708997D0 (en) | Zapo | |
GB0709375D0 (en) | Vector | |
GB0823425D0 (en) | Vectors | |
GB2445724B (en) | Strap | |
GB0609775D0 (en) | Vector | |
GB0701386D0 (en) | Improved skate | |
GB0703291D0 (en) | Irons | |
GB0701529D0 (en) | Vector alignment motor |